
Sign up to save your podcasts
Or


Please listen in as Drs. Piltin, van Akkooi, and Hyngstrom discuss relevant clinical trial presentations from ASCO 2024 annual meeting and their impressions on the implications for surgical oncologists. Abstracts results discussed include the neoadjuvant NADINA and PIVOTAL trials as well as an initial report on upfront TIL therapy for stage IV patients.
By Society of Surgical Oncology5
1212 ratings
Please listen in as Drs. Piltin, van Akkooi, and Hyngstrom discuss relevant clinical trial presentations from ASCO 2024 annual meeting and their impressions on the implications for surgical oncologists. Abstracts results discussed include the neoadjuvant NADINA and PIVOTAL trials as well as an initial report on upfront TIL therapy for stage IV patients.

43,976 Listeners

32,110 Listeners

38,232 Listeners

30,736 Listeners

1,305 Listeners

87,552 Listeners

112,191 Listeners

56,577 Listeners

19,291 Listeners

24 Listeners

244 Listeners

16,215 Listeners

61 Listeners

9,424 Listeners

37 Listeners